Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.36 |
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488871 | 0.90 | CSNK2A1 (0.41) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3488119 | 0.87 | CSNK2A1 (0.43) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3488467 | 0.85 | ALDH1A1 (0.37) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3490106 | 0.85 | ALDH1A1 (0.37) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3488802 | 0.85 | MAPT (0.36) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3488750 | 0.84 | PGR (0.47) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3488964 | 0.82 | MAPK14 (0.42) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3489968 | 0.81 | NR3C2 (0.48) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3488809 | 0.81 | ALDH1A1 (0.39) | ALDH1A1SLC34A1MAPTGAANR3C2 | |
| SCHEMBL3489611 | 0.81 | MAPT (0.52) | ALDH1A1SLC34A1MAPTGAANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | ALDH1A1 1704/4885SLC34A1 982/4885MAPT 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.